Israel Englander Millennium Management
Israel “Izzy” Englander is the founder of Millennium Management, one of the world’s largest multi-strategy hedge fund platforms. Millennium allocates capital across hundreds of independent teams rather than a single house view, with rigorous risk controls at the platform level. Englander’s model has been highly influential in the rise of pod-shop multi-manager structures across the industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$643M |
| 2 |
AT&T
T
|
+$311M |
| 3 |
State Street Technology Select Sector SPDR ETF
XLK
|
+$306M |
| 4 |
Microsoft
MSFT
|
+$292M |
| 5 |
Ametek
AME
|
+$215M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$887M |
| 2 |
Apple
AAPL
|
+$694M |
| 3 |
PRAH
PRA Health Sciences, Inc.
PRAH
|
+$616M |
| 4 |
Amazon
AMZN
|
+$596M |
| 5 |
Linde
LIN
|
+$531M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 58.05% |
| 2 | Technology | 7.69% |
| 3 | Financials | 6.83% |
| 4 | Healthcare | 6.42% |
| 5 | Industrials | 4.98% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3551
Replimune Group
REPL
$1.46B
| $2.62M | ﹤0.01% |
88,432
-31,152
| -26% | -$1.01M |
|
|
MON
3552
DELISTED
Monument Circle Acquisition Corp. Class A Common Stock
MON
| $2.62M | ﹤0.01% |
268,525
+110,000
| +69% | +$1.07M |
|
3553
PUT
Icon
ICLR
$13.1B
| $2.62M | ﹤0.01% |
10,000
+8,800
| +733% | +$2.14M |
|
3554
Marqeta
MQ
$1.71B
| $2.62M | ﹤0.01% |
29,613
-74,102
| -71% | -$7.93M |
|
|
FITB
3555
PUT
Fifth Third Bancorp
FITB
$49.5B
| $2.62M | ﹤0.01% |
61,700
+20,600
| +50% | +$789K |
|
3556
Acco Brands
ACCO
$396M
| $2.62M | ﹤0.01% |
304,705
-746,713
| -71% | -$6.58M |
|
3557
PUT
CONMED
CNMD
$1.5B
| $2.62M | ﹤0.01% |
20,000
+10,000
| +100% | +$1.31M |
|
3558
Shake Shack
SHAK
$2.82B
| $2.62M | ﹤0.01% |
+33,348
| New | +$3.03M |
|
3559
Liquidia Corp
LQDA
$6.06B
| $2.61M | ﹤0.01% |
947,039
-162,685
| -15% | -$423K |
|
|
ASLN
3560
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
| $2.61M | ﹤0.01% |
36,705
+2,973
| +9% | +$338K |
|
|
CLVS
3561
DELISTED
Clovis Oncology, Inc.
CLVS
| $2.6M | ﹤0.01% |
584,173
-1,720,201
| -75% | -$8.29M |
|
|
ISEE
3562
CALL
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $2.6M | ﹤0.01% |
+160,000
| New | +$1.74M |
|
|
TRONU
3563
DELISTED
Corner Growth Acquisition Corp. 2 Units
TRONU
| $2.6M | ﹤0.01% |
256,495
+5,705
| +2% | +$57.3K |
|
|
RC
3564
Ready Capital
RC
$302M
| $2.6M | ﹤0.01% |
179,961
+145,204
| +418% | +$2.2M |
|
|
IRAA
3565
DELISTED
Iris Acquisition Corp Class A Common Stock
IRAA
| $2.6M | ﹤0.01% |
267,397
-21,673
| -7% | -$210K |
|
|
BTRSW
3566
CALL
DELISTED
BTRS Holdings Inc. Warrants
BTRSW
| $2.59M | ﹤0.01% |
990,050
+606,300
| +158% | +$1.94M |
|
3567
Kiniksa Pharmaceuticals
KNSA
$6.09B
| $2.59M | ﹤0.01% |
227,515
-220,695
| -49% | -$2.87M |
|
3568
PUT
BlackSky Technology
BKSY
$970M
| $2.59M | ﹤0.01% |
+31,250
| New | +$2.56M |
|
3569
eHealth
EHTH
$38.4M
| $2.59M | ﹤0.01% |
63,899
+44,578
| +231% | +$2.08M |
|
|
BLU
3570
CALL
DELISTED
BELLUS Health Inc.
BLU
| $2.58M | ﹤0.01% |
+420,000
| New | +$1.59M |
|
|
ABX
3571
Abacus Global Management
ABX
$952M
| $2.58M | ﹤0.01% |
261,784
+225,000
| +612% | +$2.2M |
|
|
WEBR
3572
DELISTED
Weber Inc.
WEBR
| $2.58M | ﹤0.01% |
+146,372
| New | +$2.35M |
|
3573
iShares S&P 500 Growth ETF
IVW
$76.8B
| $2.57M | ﹤0.01% |
34,810
-9,170
| -21% | -$699K |
|
3574
JPMorgan Ultra-Short Income ETF
JPST
$40.8B
| $2.57M | ﹤0.01% |
50,649
-135,012
| -73% | -$6.85M |
|
3575
CALL
Phillips 66
PSX
$97.4B
| $2.56M | ﹤0.01% |
36,600
+200
| +0.5% | +$14.5K |
|
Similar funds
Israel Englander's Q3 2021 Portfolio in Review
As of Q3 2021, Israel Englander held 7,698 positions worth $167B, up 2.3% from $163B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Israel Englander's Q3 2021 filing shows 1,245 new, 2,719 increased, 2,446 reduced and 981 closed positions. Its largest new stake was Sight Sciences: 1,577,092 shares worth $35.8M. The largest sale was Alexion Pharmaceuticals, an estimated $887M.
By sector, the portfolio is most concentrated in Miscellaneous at 58% of assets, up from 55% a quarter earlier, followed by Technology and Financials.
- Israel Englander's largest Q3 2021 buy was Sight Sciences: 1,577,092 shares worth $35.8M.
- Israel Englander added most to State Street SPDR S&P 500 ETF Trust in Q3 2021, an estimated $643M increase.
- Israel Englander's biggest Q3 2021 reduction was Apple, cutting an estimated $694M.
- Israel Englander fully exited Alexion Pharmaceuticals in Q3 2021, selling an estimated $887M.
- Israel Englander's ten largest holdings make up 18% of its $167B portfolio in Q3 2021.
- Israel Englander opened 1,245 new positions and closed 981 in Q3 2021.
- Israel Englander's portfolio value rose 2.3% quarter-over-quarter to $167B.
Based on Millennium Management's 13F filing for Q3 2021, filed 15 Nov 2021.